Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab in Cystic Fibrosis
NCT02759562Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of andecaliximab in cystic fibrosis (CF) (6 arms), sponsored by Gilead Sciences. Primary endpoint: Absolute Change in Pre-bronchodilator FEV1 Percent Predicted From Baseline to Week 8. Started Nov 2016; status: terminated.
02
Drugs
andecaliximab
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02759562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759562.